Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Gross Margin (2023 - 2025)

Historic Gross Margin for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Q3 2025 value amounting to 87.5%.

  • Phathom Pharmaceuticals' Gross Margin rose 19000.0% to 87.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 87.25%, marking a year-over-year increase of 37100.0%. This contributed to the annual value of 85.57% for FY2024, which is 100600.0% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Gross Margin stood at 87.5%, which was up 19000.0% from 87.25% recorded in Q2 2025.
  • Phathom Pharmaceuticals' Gross Margin's 5-year high stood at 87.5% during Q3 2025, with a 5-year trough of 75.51% in Q4 2023.
  • Its 3-year average for Gross Margin is 83.61%, with a median of 86.27% in 2025.
  • Per our database at Business Quant, Phathom Pharmaceuticals' Gross Margin soared by 116300bps in 2024 and then soared by 19000bps in 2025.
  • Phathom Pharmaceuticals' Gross Margin (Quarter) stood at 75.51% in 2023, then rose by 15bps to 87.14% in 2024, then increased by 0bps to 87.5% in 2025.
  • Its Gross Margin was 87.5% in Q3 2025, compared to 87.25% in Q2 2025 and 86.94% in Q1 2025.